Articles

An update on the POLLUX study has shown that daratumumab, lenalidomide, and dexamethasone improves efficacy outcomes in patients with relapsed/refractory multiple myeloma (RRMM).

The 4-year follow-up of the ELOQUENT-2 study examining elotuzumab plus lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) shows sustained safety and efficacy results.

Researchers from the CASTOR trial provided an update on the efficacy and safety of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).

This study examined the trends in survival and healthcare costs of US patients with multiple myeloma from 2006 to 2014.

A systematic literature review and network meta-analysis were conducted to determine the comparative efficacy of multiple myeloma (MM) therapies for treating first relapse.

This study provides a closer look at the racial differences in fluorescence in situ hybridization (FISH) abnormalities in minorities with multiple myeloma.

The combination of daratumumab plus lenalidomide and dexamethasone is associated with the greatest progression-free survival life-years and quality-adjusted life-years versus combinations including carfilzomib, ixazomib, and elotuzumab with relapsed/refractory multiple myeloma (RRMM).

At the Best Practices in Lung Cancer Navigation Summit, held October 22, 2016, in Rosemont, IL, oncology nurse navigators involved in the care of patients with lung cancer convened to discuss the complexities and role of nurse navigators in the treatment of lung cancer.